2.27

2.58% -0.06

Lakewood Amedex Biotherapeutics Inc (LABT)

Overview News Price History Discussions Forecast

Lakewood Amedex Biotherapeutics Inc stock is traded at $2.27, with a volume of 105.03K. It is down -2.58% in the last 24 hours and down -10.98% over the past month. Lakewood-Amedex Biotherapeutics Inc is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials - the Bisphosphocin class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. The company's main product is Nu-3, a topically delivered antimicrobial gel in Phase 2 clinical trials for the treatment of mildly infected diabetic foot ulcers (iDFU). It is also advancing a portfolio of early-stage pipeline compounds developed from its Bisphosphocin platform targeting potential disease indications, including complicated urinary tract infection (cUTI) and pulmonary infections.

Previous Close:

$2.33

Open:

$2.33

24h Volume:

105.03K

Relative Volume:

0.05

Market Cap:

$3.97M

Revenue:

Net Income/Loss:

$-4.23M

P/E Ratio:

-0.258

EPS:

-8.8

Net Cash Flow:

$-1.89M

1W Performance:

+2.25%

1M Performance:

-10.98%

6M Performance:

+0.00%

1Y Performance:

+0.00%

1-Day Range:

$2.0707

$2.33

1-Week Range:

$2.0707

$2.46

52-Week Range:

$0.366

$9.40

Lakewood Amedex Biotherapeutics Inc Stock (LABT) Company Profile

Name

Lakewood Amedex Biotherapeutics Inc

Sector

Healthcare (1080)

Industry

Biotechnology (604)

Phone

(941) 225-2515

Address

8031 COOPER CREEK BLVD., UNIVERSITY PARK

Employee

Twitter

Next Earnings Date

2026-08-28

Latest SEC Filings

LABT's Discussions on Twitter

Compare LABT vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
LABT Lakewood Amedex Biotherapeutics Inc	2.27	4.13M	0	-4.23M	-1.89M	-8.80
VRTX Vertex Pharmaceuticals Inc	505.75	133.25B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	803.48	82.16B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	851.29	54.80B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	203.71	43.99B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	347.48	40.62B	5.76B	514.49M	1.10B	4.4813

Lakewood Amedex Biotherapeutics Inc Stock (LABT) Latest News

Aug 14, 2026

Lakewood-Amedex Biotherapeutics (LABT) investor WFI Equity discloses 8.8% ownership stake - Stock Titan

Aug 14, 2026

Lakewood-Amedex Raises $7.5M and Lists on NASDAQ, Shedding $1.5M Debt - Minichart

Aug 14, 2026

LABT: Q2 net loss rose sharply on higher R&D and G&A costs; liquidity improved after Series C financing - TradingView

Aug 14, 2026

Lakewood-Amedex Biotherapeutics Inc. Q2 2026: Revenue $0 Net loss $(3.90M), EPS $(2.75) — 10-Q Summary - TradingView

Aug 14, 2026

Lakewood-Amedex (NASDAQ: LABT) raises $7.5M, expands cash yet flags going concern - Stock Titan

Aug 14, 2026

Aug 13, 2026

Upcoming and recent IPOs – IPOs calendar - Yahoo Finance Australia

Aug 13, 2026

Aug 11, 2026

Lakewood-Amedex Biotherapeutics (LABT) Stock Trends and Sentiment 2026 $LABT - MarketBeat

Aug 11, 2026

Aug 10, 2026

Lakewood-Amedex Biotherapeutics announces annual shareholder meeting - Bitget

Aug 10, 2026

Lakewood-Amedex (NASDAQ: LABT) seeks 100M share authorization and reverse split power - Stock Titan

Aug 10, 2026

Aug 06, 2026

Lindesfarne LLC reports 8.582% LABT stake in Lakewood-Amedex Biotherapeutics (LABT) filing - Stock Titan

Aug 06, 2026

Lakewood-Amedex Biotherapeutics (LABT) Earnings Date and Reports 2026 $LABT - MarketBeat

Aug 06, 2026

Jul 24, 2026

Lakewood-Amedex Biotherapeutics Inc. Revenue Breakdown – NASDAQ:LABT - TradingView

Jul 24, 2026